What should I do if I am resistant to Ponatinib?

Ponatinib (Ponatinib) is a pan-tyrosine kinase inhibitor (TKI) that is effective in patients with multi-refractory chronic myelogenous leukemia (CML) who have failed other TKIs. Although response rates are high, resistance or intolerance may develop. Allogeneic stem cell transplantation (SCT) should be considered in all patients after ponatinib failure, perhaps even earlier.

Omacetin can be used in patients who have received at least TKI treatment twice or patients with T315I. Omacetaxine has been used to treat patients with chronic myelogenous leukemia for many years with some success. For patients resistant to ponatinib, a promising treatment is ABL001, a novel allosteric inhibitor of BCR-ABL1 kinase activity. Patients who are resistant or intolerant to ponatinib have a poor prognosis, are extremely unlikely to respond to subsequent treatments, and have a short survival period. However, everyone’s physique is different and their resistance to drugs is also different. If you are not suitable for it, please inform your doctor in time.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.